Nodexus Inc. Emerges From Stealth With $30 Million Series A Funding To Advance Manufacturing And Expand Commercialization Of Nx One Platform

Dec 16, 2021•over 3 years ago

Amount Raised

$30 Million

Round Type

series a

San Jose

Description

Nodexus Inc., an emerging leader in the development of automated live cell characterization and isolation technologies, has raised an oversubscribed $30M Series A financing that will allow the company to expand manufacturing of its flagship NX One platform as well as build its commercialization capabilities and pipeline to meet surging demand. The financing was led by RA Capital Management with participation by Section 32 as well as previous investors. The company also announced the appointment of William Rhodes to the Board of Directors.

Company Information

Company

Nodexus

Location

San Jose, California, United States

About

Nodexus is a life science tools company that develops platforms to accelerate biological workflows and make them more widely accessible. The company leverages a proprietary technology suite consisting of microfluidic cartridges, hardware instruments, and software offerings. Nodexus’ flagship NX One platform offers integrated, easy-to-use, and affordable automated cell isolation for applications in industry, clinical research, and academia including cell line and antibody development, CRISPR engineering, single-cell genomics, synthetic biology, and more. For more information regarding the company, please visit Nodexus.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Nodexus Inc. Emerges From Stealth With $30 Million Series A Funding To Advance Manufacturing And Expand Commercialization Of Nx One Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information